Why The Private GP Group work with Berkeley Genetics…
- Berkeley Genetics is a leading UK distributor of genetic cancer testing with a vision to make these services available to all.
- They strive to make genetic testing services accessible to all. Tests can be purchased directly from them – with or without a referral.
- They offer clinical-grade genetic cancer testing services aligned with UK and internationally acclaimed laboratories; such as Informed Genomics, Invitae and Reveal Genomics.
- Berkeley Genetics offers pre and post-test clinical support, giving information about the process from start to finish as well as helping you understand your results.
What tests are available?
Comprehensive Hereditary Cancer Panel
This comprehensive genetic panel analyses a wide range of genes associated with the risk of 12 familial cancers, including breast, colorectal, gastrointestinal, melanoma, ovarian, pancreatic, prostate, renal, non-melanoma skin, stomach, uterine, and womb cancers.
£499
This comprehensive genetic panel analyses a wide range of genes associated with the risk of familial cancers, including breast, colorectal, gastrointestinal, melanoma, ovarian, pancreatic, prostate, renal, non-melanoma skin, stomach, uterine, and womb cancers. You may have been diagnosed with one of these cancers and want to understand if this is due to an inherited faulty gene. You may have a strong family history/close family relative diagnosed with cancer and want to know if you are at risk, or you may not have a personal history of the diseases or known family history but are being proactive about your health.
The test confirms the presence of genetic variants in a diagnosed cancer patient and helps identify increased cancer risk in immediate relatives. It is also suitable for anyone with or without cancer, or even a family history of cancer, helping to detect inherited genetic variants that may increase their risk. This is a saliva test which you can take when convenient which is simple, quick, easy, with step-by-step instructions. Testing takes 15 working days from the time that the sample arrives at our laboratory.
APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, VHL
(Genes included are open to being updated in line with leading world knowledge occasionally)
There are three possible outcomes from this test:
The test results may come back negative. This means that the test has not identified any faults in the genes analysed. So, you are not at an increased risk of any of the common cancers caused by a known inherited fault in the genes we have tested.
The test result could show you have a Variant of Uncertain Significance, an inconclusive result. Also known as a VUS. If you have a variant of uncertain significance or VUS, this means a variant of uncertain significance has been identified in one of the genes analysed.
The other possible outcome may show you have a variant detected test result. This means that a fault in one or more of your genes has been found, which shows you have an increased risk of developing a particular cancer.
genetic expert if required.
Post-test clinical support for patients with a negative and VUS result is provided by an informational video with the option to arrange a call with a genetic expert if required. For patients with a positive result, clinical support is provided by a genetic expert by a pre-arranged private consultation. An individual will not receive any results or report until this consultation has taken place.
All pre and post-test clinical support is included in the test kit price.
This test is for over 18-year-olds only. It is suitable for individuals affected or unaffected by a current cancer diagnosis.
Hereditary Breast and Gynaecological Cancer Panel
Tests for variants in genes predominantly associated with an increased risk of breast, ovarian, uterine and womb cancers.
£449
The Hereditary Breast and Gynaecological Cancer Panel analyses well-established genes that are associated with an elevated risk of developing breast, ovarian, uterine and womb cancer. By analysing these genes, this panel enables the early determination of risk of a second primary in affected patients, helping to inform surgical and treatment decisions. Also suitable for testing immediate relatives of a known carrier to identify hereditary breast, ovarian, uterine and womb cancer risk.
The test confirms the presence of genetic variants in diagnosed cancer patients and helps identify increased cancer risk in immediate relatives of the patient. It is also suitable for individuals with or without a family history of cancer, helping to detect inherited genetic variants that may increase their risk. This is a saliva test which you can take when convenient which is simple, quick, easy, with step-by-step instructions. Testing takes 15 working days from the time that the sample arrives at our laboratory.
ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, MLH1, MSH2, MSH6, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
(Genes included are open to being updated in line with leading world knowledge occasionally)
There are three possible outcomes from this test:
The test results may come back negative. This means that the test has not identified any faults in the genes analysed. So, you are not at an increased risk of any of the common cancers caused by a known inherited fault in the genes we have tested.
The test result could show you have a Variant of Uncertain Significance, an inconclusive result. Also known as a VUS. If you have a variant of uncertain significance or VUS, this means a variant of uncertain significance has been identified in one of the genes analysed.
The other possible outcome may show you have a variant detected test result. This means that a fault in one or more of your genes has been found, which shows you have an increased risk of developing a particular cancer.
This test is for over 18-year-olds only. It is suitable for individuals affected or unaffected by a current cancer diagnosis.
Hereditary Breast Cancer Panel
Tests for variants in genes predominantly associated with an increased risk of breast and ovarian cancers as a second primary in diagnosed breast cancer patients.
£449
The Hereditary Breast Cancer Panel analyses 11 well-established genes that are associated with an elevated risk of developing breast and ovarian cancer. By analysing these genes, this panel enables the early determination of risk of a second primary in affected patients, helping to inform surgical and treatment decisions. Also suitable for testing immediate relatives of a known carrier to identify hereditary breast and ovarian cancer risk.
The test confirms the presence of genetic variants in diagnosed cancer patients and helps identify increased cancer risk in immediate relatives of the patient. It is also suitable for individuals with or without a family history of cancer, helping to detect inherited genetic variants that may increase their risk. This is a saliva test which you can take when convenient which is simple, quick, easy, with step-by-step instructions. Testing takes 15 working days from the time that the sample arrives at our laboratory.
ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
(Genes included are open to being updated in line with leading world knowledge occasionally)
There are three possible outcomes from this test:
The test results may come back negative. This means that the test has not identified any faults in the genes analysed. So, you are not at an increased risk of any of the common cancers caused by a known inherited fault in the genes we have tested.
The test result could show you have a Variant of Uncertain Significance, an inconclusive result. Also known as a VUS. If you have a variant of uncertain significance or VUS, this means a variant of uncertain significance has been identified in one of the genes analysed.
The other possible outcome may show you have a variant detected test result. This means that a fault in one or more of your genes has been found, which shows you have an increased risk of developing a particular cancer.
This test is for over 18-year-olds only. It is suitable for individuals affected or unaffected by a current cancer diagnosis.
Hereditary Pancreatic Cancer Panel
Tests for variants in genes predominantly associated with an increased risk of pancreatic cancer.
£449
The Hereditary Pancreatic Cancer Panel analyses well-established genes that are associated with an increased risk of developing pancreatic cancer. By analysing these genes, this panel enables the early determination of risk of a second primary in affected patients, helping to inform surgical and treatment decisions. Also suitable for testing immediate relatives of a known carrier to identify hereditary pancreatic cancer risk.
The test confirms the presence of genetic variants in diagnosed cancer patients and helps identify increased cancer risk in immediate relatives of the patient. It is also suitable for individuals with or without a family history of cancer, helping to detect inherited genetic variants that may increase their risk. This is a saliva test which you can take when convenient which is simple, quick, easy, with step-by-step instructions. Testing takes 15 working days from the time that the sample arrives at our laboratory.
APC, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, TP53, VHL
(Genes included are open to being updated in line with leading world knowledge occasionally)
There are three possible outcomes from this test:
The test results may come back negative. This means that the test has not identified any faults in the genes analysed. So, you are not at an increased risk of any of the common cancers caused by a known inherited fault in the genes we have tested.
The test result could show you have a Variant of Uncertain Significance, an inconclusive result. Also known as a VUS. If you have a variant of uncertain significance or VUS, this means a variant of uncertain significance has been identified in one of the genes analysed.
The other possible outcome may show you have a variant detected test result. This means that a fault in one or more of your genes has been found, which shows you have an increased risk of developing a particular cancer.
This test is for over 18-year-olds only. It is suitable for individuals affected or unaffected by a current cancer diagnosis.
Hereditary Colorectal Cancer Panel (inc. Lynch syndrome)
Tests for variants in genes predominantly associated with an increased risk of colorectal cancer, including Lynch syndrome.
£449
The Hereditary Colorectal Cancer Panel analyses well-established genes that are associated with an increased risk of developing colorectal cancer. This panel includes genes known to be linked to Lynch Syndrome. Lynch syndrome is an inherited condition that increases a person’s risk of developing colorectal cancer and other forms of cancer before the age of 50 years. By analysing these genes, this panel enables the early determination of risk of a second primary in affected patients, helping to inform surgical and treatment decisions. Also suitable for testing immediate relatives of a known carrier to identify hereditary colorectal cancer risk.
The test confirms the presence of genetic variants in diagnosed cancer patients and helps identify increased cancer risk in immediate relatives of the patient. It is also suitable for individuals with or without a family history of cancer, helping to detect inherited genetic variants that may increase their risk. This is a saliva test which you can take when convenient which is simple, quick, easy, with step by step instructions. Testing takes 15 working days from the time that the sample arrives at our laboratory.
APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
(Genes included are open to being updated in line with leading world knowledge occasionally)
There are three possible outcomes from this test:
The test results may come back negative. This means that the test has not identified any faults in the genes analysed. So, you are not at an increased risk of any of the common cancers caused by a known inherited fault in the genes we have tested.
The test result could show you have a Variant of Uncertain Significance, an inconclusive result. Also known as a VUS. If you have a variant of uncertain significance or VUS, this means a variant of uncertain significance has been identified in one of the genes analysed.
The other possible outcome may show you have a variant detected test result. This means that a fault in one or more of your genes has been found, which shows you have an increased risk of developing a particular cancer.
This test is for over 18-year-olds only. It is suitable for individuals affected or unaffected by a current cancer diagnosis.
Hereditary Prostate Cancer Panel
Tests for variants in genes predominantly associated with an increased risk of prostate cancer.
£449
The Hereditary Prostate Cancer Panel analyses well-established genes that are associated with an elevated risk of developing prostate cancer. By analysing these genes, this panel enables the early determination of risk of a second primary in affected patients, helping to inform surgical and treatment decisions. Also suitable for testing immediate relatives of a known carrier to identify hereditary prostate cancer risk.
The test confirms the presence of genetic variants in diagnosed cancer patients and helps identify increased cancer risk in immediate relatives of the patient. It is also suitable for individuals with or without a family history of cancer, helping to detect inherited genetic variants that may increase their risk. This is a saliva test which you can take when convenient which is simple, quick, easy, with step-by-step instructions. Testing takes 15 working days from the time that the sample arrives at our laboratory.
ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6
(Genes included are open to being updated in line with leading world knowledge occasionally)
There are three possible outcomes from this test:
The test results may come back negative. This means that the test has not identified any faults in the genes analysed. So, you are not at an increased risk of any of the common cancers caused by a known inherited fault in the genes we have tested.
The test result could show you have a Variant of Uncertain Significance, an inconclusive result. Also known as a VUS. If you have a variant of uncertain significance or VUS, this means a variant of uncertain significance has been identified in one of the genes analysed.
The other possible outcome may show you have a variant detected test result. This means that a fault in one or more of your genes has been found, which shows you have an increased risk of developing a particular cancer.
This test is for over 18-year-olds only. It is suitable for individuals affected or unaffected by a current cancer diagnosis.
Hereditary Melanoma Cancer Panel
Tests for variants in well-established genes that are associated with an elevated risk of developing melanoma (both skin and non-skin melanoma).
£449
The Hereditary Melanoma Cancer Panel analyses well-established genes that are associated with an elevated risk of developing melanoma. By analysing these genes, this panel enables the early determination of risk of a second primary in affected patients, helping to inform surgical and treatment decisions. Also suitable for testing immediate relatives of a known carrier to identify hereditary melanoma risk.
The test confirms the presence of genetic variants in diagnosed cancer patients and helps identify increased cancer risk in immediate relatives of the patient. It is also suitable for individuals with or without a family history of cancer, helping to detect inherited genetic variants that may increase their risk. This is a saliva test which you can take when convenient which is simple, quick, easy, with step-by-step instructions. Testing takes 15 working days from the time that the sample arrives at our laboratory.
BAP1, BRCA2, CDK4, CDKN2A, PTEN
(Genes included are open to being updated in line with leading world knowledge occasionally)
There are three possible outcomes from this test:
The test results may come back negative. This means that the test has not identified any faults in the genes analysed. So, you are not at an increased risk of any of the common cancers caused by a known inherited fault in the genes we have tested.
The test result could show you have a Variant of Uncertain Significance, an inconclusive result. Also known as a VUS. If you have a variant of uncertain significance or VUS, this means a variant of uncertain significance has been identified in one of the genes analysed.
The other possible outcome may show you have a variant detected test result. This means that a fault in one or more of your genes has been found, which shows you have an increased risk of developing a particular cancer.
This test is for over 18-year-olds only. It is suitable for individuals affected or unaffected by a current cancer diagnosis.